<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bcl-xL is a pro-survival member of the Bcl-2 family that plays indispensable roles in regulating cell survival and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>It is overexpressed in many <z:mp ids='MP_0002018'>malignant tumors</z:mp> including <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>However, it is still unclear if Bcl-xL can be used as an independent molecular marker for predicting the prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, reverse transcription-PCR assay was performed to detect the expression of Bcl-xL <z:chebi fb="2" ids="33699">mRNA</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and corresponding non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> colon tissues </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemistry was performed to detect the immunolocalization of Bcl-xL protein in sixty-eight primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissue samples </plain></SENT>
<SENT sid="5" pm="."><plain>The association between Bcl-xL protein expression and clinicopathological factors of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients was analyzed and the survival was assessed by the Kaplan-Meier method and proportional hazards model </plain></SENT>
<SENT sid="6" pm="."><plain>The averaged level of Bcl-xL <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues (0.85±0.13) was significantly higher than that in non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> colon tissues (0.08±0.02) </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemical staining showed that the Bcl-xL protein was mainly located in the cytoplasm of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>The level of Bcl-xL protein expression was closely correlated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation (P=0.002), lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P=0.010), venous permeation (P=0.004), and Duke's classification (P=0.021) </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, patients with high Bcl-xL expression showed poorer overall survival than those with low Bcl-xL expression (P=0.016) </plain></SENT>
<SENT sid="10" pm="."><plain>Univariate and multivariate analysis indicated that the status of Bcl-xL protein expression might be an independent prognostic marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (P=0.032) </plain></SENT>
<SENT sid="11" pm="."><plain>Taken together, immunohistochemical assessment of status of Bcl-xL protein may offer a valuable approach for predicting survival after curative surgery for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>